The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

Inclusion Criteria Patients must have: * History of HIV seropositivity. * Disseminated MAC. * Positive blood culture for MAC within 4 weeks prior to study entry. * Consent of parent or guardian if less than 18 years of age. * Ability to complete the study. NOTE: * Patients with active opportunistic infections other than dMAC are permitted if dosage and clinical parameters have been stable for 4 weeks prior to enrollment. Exclusion Criteria Concurrent Medication: Excluded: * Active therapy with carbamazepine or theophylline, unless investigator agrees to carefully monitor blood levels. * Active therapy with investigational drugs other than treatment for HIV disease, except with approval of the sponsor. * Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal). * Amikacin. * Azithromycin. * Capreomycin. * Ciprofloxacin. * Cycloserine. * Ethionamide. * Gentamicin. * Kanamycin. * Levofloxacin. * Lomefloxacin. * Ofloxacin. * Rifampin. * Rifabutin. * Sparfloxacin. * Streptomycin. * Any other aminoglycosides, quinolones, and macrolides. Patients with the following prior conditions are excluded: History of allergy or hypersensitivity to macrolides, ethambutol, or clofazimine. Prior Medication: Excluded: * Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other macrolides (such as clindamycin), quinolones, and rifampin, between screening and study entry. * Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more than 14 days cumulative within the past 2 months.